guest ::
| Home > Publications database > Wuhan strain of SARS-CoV-2 triggers activation of immune evasion machinery similar to the one operated by cancer cells. > print |
| Home > Publications database > Wuhan strain of SARS-CoV-2 triggers activation of immune evasion machinery similar to the one operated by cancer cells. > print |
| 001 | 302873 | ||
| 005 | 20250720021523.0 | ||
| 024 | 7 | _ | |a 10.3389/fimmu.2025.1599352 |2 doi |
| 024 | 7 | _ | |a pmid:40607414 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12213721 |2 pmc |
| 024 | 7 | _ | |a altmetric:177404539 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01413 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Abooali, Maryam |b 0 |
| 245 | _ | _ | |a Wuhan strain of SARS-CoV-2 triggers activation of immune evasion machinery similar to the one operated by cancer cells. |
| 260 | _ | _ | |a Lausanne |c 2025 |b Frontiers Media |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1752748801_14022 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a In the last 2 years, there has been an increasing concern that SARS-CoV-2 infection may represent a marker of undiagnosed cancers. A potential connection between COVID-19/long COVID and malignant transformation/cancer progression was reported in a number of studies. It is, however, unclear if the virus itself can cause malignant transformation or if it has a potential to support malignant processes in human body. We analyzed nasopharyngeal swabs collected from individuals infected with Wuhan strain of SARS-CoV-2 and conducted in vitro studies using BEAS-2B human bronchial epithelial cells. Here we report that Wuhan strain of SARS-CoV-2 and its spike protein induce activation of hypoxia-inducible factor 1 (HIF-1) transcription complex in infected cells. This effect is achieved through conversion of cellular 2-oxoglutarate into 2-hydroxy-glutarate, which most likely blocks the activity of HIF-1α prolyl hydroxylation. As such, it leads to activation of HIF-1, which triggers production of transforming growth factor-β type 1 (TGF-β). TGF-β induces expression of immune checkpoint proteins, such as galectin-9, programmed death-ligand 1, and indoleamine-2,3-dioxygenase, an enzyme, which is involved in production of immunosuppressive amino acid called L-kynurenine. These immune checkpoint pathways were capable of suppressing both helper and cytotoxic activities of T lymphocytes and, as such, could potentially support malignant processes in infected tissues. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a COVID-19 |2 Other |
| 650 | _ | 7 | |a SARS-CoV-2 |2 Other |
| 650 | _ | 7 | |a cancer |2 Other |
| 650 | _ | 7 | |a immune checkpoints |2 Other |
| 650 | _ | 7 | |a immune evasion |2 Other |
| 650 | _ | 7 | |a Hypoxia-Inducible Factor 1, alpha Subunit |2 NLM Chemicals |
| 650 | _ | 7 | |a HIF1A protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM Chemicals |
| 650 | _ | 7 | |a Indoleamine-Pyrrole 2,3,-Dioxygenase |2 NLM Chemicals |
| 650 | _ | 7 | |a spike protein, SARS-CoV-2 |2 NLM Chemicals |
| 650 | _ | 7 | |a B7-H1 Antigen |2 NLM Chemicals |
| 650 | _ | 7 | |a Ketoglutaric Acids |2 NLM Chemicals |
| 650 | _ | 7 | |a CD274 protein, human |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a SARS-CoV-2: immunology |2 MeSH |
| 650 | _ | 2 | |a COVID-19: immunology |2 MeSH |
| 650 | _ | 2 | |a COVID-19: virology |2 MeSH |
| 650 | _ | 2 | |a Immune Evasion: immunology |2 MeSH |
| 650 | _ | 2 | |a Hypoxia-Inducible Factor 1, alpha Subunit: metabolism |2 MeSH |
| 650 | _ | 2 | |a Spike Glycoprotein, Coronavirus: immunology |2 MeSH |
| 650 | _ | 2 | |a Spike Glycoprotein, Coronavirus: metabolism |2 MeSH |
| 650 | _ | 2 | |a Indoleamine-Pyrrole 2,3,-Dioxygenase: metabolism |2 MeSH |
| 650 | _ | 2 | |a Epithelial Cells: immunology |2 MeSH |
| 650 | _ | 2 | |a Epithelial Cells: virology |2 MeSH |
| 650 | _ | 2 | |a Cell Line |2 MeSH |
| 650 | _ | 2 | |a B7-H1 Antigen: metabolism |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: immunology |2 MeSH |
| 650 | _ | 2 | |a Ketoglutaric Acids: metabolism |2 MeSH |
| 700 | 1 | _ | |a Yasinska, Inna M |b 1 |
| 700 | 1 | _ | |a Thapa, Gauri |b 2 |
| 700 | 1 | _ | |a Lei, Xi |b 3 |
| 700 | 1 | _ | |a da Costa, Kelly A S |b 4 |
| 700 | 1 | _ | |a Schlichtner, Stephanie |0 P:(DE-He78)0b6e32bf4b6d335c6b11d5edaef8bfd3 |b 5 |u dkfz |
| 700 | 1 | _ | |a Berger, Steffen M |b 6 |
| 700 | 1 | _ | |a Fasler-Kan, Elizaveta |b 7 |
| 700 | 1 | _ | |a Temperton, Nigel J |b 8 |
| 700 | 1 | _ | |a Vuono, Romina |b 9 |
| 700 | 1 | _ | |a Sumbayev, Vadim V |b 10 |
| 773 | _ | _ | |a 10.3389/fimmu.2025.1599352 |g Vol. 16, p. 1599352 |0 PERI:(DE-600)2606827-8 |p 1599352 |t Frontiers in immunology |v 16 |y 2025 |x 1664-3224 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:302873 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)0b6e32bf4b6d335c6b11d5edaef8bfd3 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b FRONT IMMUNOL : 2022 |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-12-29T15:23:07Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-12-29T15:23:07Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-12-29T15:23:07Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2023-12-29T15:23:07Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-28 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b FRONT IMMUNOL : 2022 |d 2024-12-28 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-28 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-28 |
| 920 | 1 | _ | |0 I:(DE-He78)A420-20160331 |k A420 |l Personalisierte Medizinische Onkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A420-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|